A story published online today in The New York Times Magazine features SomaLogic and describes how measuring thousands of blood proteins could impact diagnostic testing and health screening. The Boulder-based author, Michael Behar, participated in a trial that used SomaLogic’s technology to assess cardiovascular health. Behar’s interest in the study was prompted by concerns about his own health after his mother suffered a fatal heart attack, despite being classified as very low risk based on traditional measures.

The pilot study described in the article screened patients using a SomaLogic test that measured the levels of a group of blood proteins and determined the likelihood of having a cardiovascular event, such as a heart attack or stroke within five years. Unlike genes which remain largely static throughout a person’s lifetime, the proteins in the body are constantly changing in response to both internal and external factors (e.g. infection, disease, diet, exercise, medication, etc.). Proteins can thus provide health information in real-time, including the earliest onset of disease.

The story will appear in the print edition of The New York Times Magazine on Sunday, November 18 and can be accessed online here:

“Proteomics Might Have Saved My Motherʼs Life. And It May Yet Save Mine”
Behar, M. The New York Times Magazine (2018, November).

 

Please note:
The SOMAscan® platform is not commercially available for individuals or health providers at this time. In addition, the SOMAscan Assay and Reports are currently For Research Use Only worldwide and for Investigational Use Only in certain geographies. They are not for use in diagnostic procedures outside of current investigational studies. Change in intended use and marketing status will be provided when available.

We welcome you to provide your name and contact information if you are interested in staying up-to-date on our progress toward that goal.  We will only use your name and contact information for the purpose of contacting you with more information about the SOMAscan platform.